“Long-acting” olanzapine in maintenance therapy of schizophrenia: A study with plasma levels

References

• American Psychiatric Association. 2000. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR). Washington, DC American Psychiatric Association.
   Google Scholar
• Ascher-Svanum H, Novick D, Haro JM, Bertsch J, McDonnel D, Detke HC. 2014. Long-term functional improvements in 2-year treatment of schizophrenia outpatients with olanzapine long-acting injection. Neuropsych Dis Treat 10:1125–1131.
   PubMed Web of Science ®Google Scholar
• Citrome L. 2009. Olanzapine pamoate: a stick in time? A review of the efficacy and safety profile of a new profile of a new depot formulation of a second-generation antipsycothic. Int J Clin Pract 63:140–150.
   Google Scholar
• Coldham EL, Addington J, Addington D. 2002. Medication adherence of individuals with a first episode of psychosis. Acta Psychiatr Scand 106:286–290.
   PubMed Web of Science ®Google Scholar
• Detke HC, McDonnell DP, Brunner E, Zhao F, Sorsaburu S, Stefaniak VJ, Corya SA. 2010. Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, I: analysis of cases. BMC Psychiatry 10:43.
   PubMed Web of Science ®Google Scholar
• Detke HC, Zhao F, Witte MM. 2012. Efficacy of olanzapine long-acting injection in patients with acutely exacerbated schizophrenia: an insight from effect size comparison with historical oral data. BMC Psychiatry 12:51.
   PubMedGoogle Scholar
• Detke HC, Weiden PJ, Llorca PM, Choukour M, Watson SB, Brunner E, Ascher-Svanum H. 2014. Comparison of olanzapine long-acting injection and oral olanzapine: a 2-year randomized, open label study in outpatients with schizophrenia. J Clin Psychopharmacol 34:426–434.
   PubMed Web of Science ®Google Scholar
• De Berardis D, Marini S, Carano A, Lang AP, Cavuto M, Piersanti M, et al. 2013. Efficacy and safety of long-acting injectable atypical antipsychotics: a review. Curr Clin Pharmacol 8:256–264.
   PubMedGoogle Scholar
• Di Lorenzo R, Brogli A. 2010. Profile of Olanzapine long-acting injection for the maintenance treatment of adult patients with schizophrenia. Neuropsychiat Dis Treat 6:573–581.
   PubMed Web of Science ®Google Scholar
• Fleischhacker WW, Keet IP, Kahn RS, EUFEST Steering Committee. 2005. The European First Episode Schizophrenia Trial (EUFEST): rationate and design of the trial. Schizophr Res 78:147–156.
   PubMed Web of Science ®Google Scholar
• Haddad PM, Lambert T, Lauriello J. 2011. Antipsychotic long-acting injections. New York: Oxford University Press,
   Google Scholar
• Hedlund JL, Vieweg BW. 1980. The Brief Psychiatric Rating Scale (BPRS): a comprehensive review. J Operat Psychiat 11:48–65.
   Google Scholar
• Kay SR, Fiszbein A, Opler LA. 1987. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 13:261–276.
   PubMed Web of Science ®Google Scholar
• Kirson NY, Weiden PJ, Yemarkov S, Huang W, Samuelson T, Offors SJ, et al. 2013. Efficacy and effectiveness of depot versus oral antipsychotics in schizophrenia: synthesizing results across different research design. J Clin Psychiatry 16:479–489.
   Google Scholar
• Leucht C, Heres ES, Kane JM, Kissling W, Davis JM, Leucht S. 2011. Oral versus depot antipsychotic drugs for schizophrenia. A critical systematic review and meta-analysis of randomised long-term trials. Schizophr Res 127:83–92.
   Google Scholar
• Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. 2005. For the clinical antipsychotic trial of intervention effectiveness (CATIE) investigators. Effectiveness of antipsychotic drug in patient with chronic schizophrenia. N Engl J Med 353:1209–1223.
   PubMed Web of Science ®Google Scholar
• Lindenmayer JP. 2010. Long-acting injectable antipsychotics: focus on olanzapine pamoate. Neuropsychiat Dis Treat 6:261–267.
   PubMed Web of Science ®Google Scholar
• Lykke J, Hesse M, Austin SF, Oestrich I. 2008. Validity of the BPRS, the BDI and the BAI in dual diagnosis patients. Add Behav 33:292–300.
   PubMed Web of Science ®Google Scholar
• Mauri MC, Steinhilber CPC, Marino R, Invernizzi E, Fiorentini A, Cerveri G, et al. 2005. Clinical outcome and olanzapine plasma levels in acute schizophrenia. Eur Psychiatry 20:55–60.
   PubMed Web of Science ®Google Scholar
• Mauri MC, Colasanti A, Rossattini M, Moliterno D, Baldi ML, Papa P. 2006. A single-blind, randomized comparison of olanzapine at a starting dose of 5 mg verus 20 mg in acute schizophrenia. Clin Neuropharmacol 29:126–131.
   PubMedGoogle Scholar
• Mauri MC, Moliterno D, Rossattini M, Colasanti A. 2008. Depression in schizophrenia: comparison of first- and second-generation antipsychotic drugs. Schizophr Res 99:7–12.
   PubMedGoogle Scholar
• McDonnell DP, Scott WA, Detke HC, Zhao F, Watson SB. 2011. Long-term safety and tolerability of open-label olanzapine long-acting injection in the treatment of schizophrenia: 190-week interim results. Clin Med Ins Psychiat 3:37–47.
   Google Scholar
• Mitchell M, Kothare P, Bergstrom R, Zhao F, Jen KY, Walker D, et al. 2013. Single- and multiple-dose pharmacokinetic, safety, and tolerability profiles of olanzapine long-acting injection: an opel-label, multicenter; nonrandomized study in patients with schizophrenia. Clin Ther 35:1890–908.
   PubMed Web of Science ®Google Scholar
• National Institute for Clinical Excellent Schizophrenia. 2002. Core intervention in the treatment and management of schizophrenia in primary and secondary care. Clinical guideline no.1:December.
   Google Scholar
• Novakovic V, Tymaz A, Peselow E, Lyndenmayer JP. 2013. Long-acting injectable antipsychotics and the development of postinjection delirium/sedation syndrome (PDSS). Clin Neuropharmacol 36:59–62.
   PubMed Web of Science ®Google Scholar
• Novik D, Haro JM, Suarez D, Perez V, Dittmann RW, Haddad PM. 2010. Predictors and clinical consequences of non-adherence with antipsychotic medication in the outpatient treatment of schizophrenia. Psychiat Res 76:109–113.
   Google Scholar
• Overall JE, Gorham DR. 1988. The brief psychiatric rating scale: Recent developments in ascertainment and scaling. Psychopharmacol Bull 24:97–99.
   Web of Science ®Google Scholar
• Perkins DO, Gu H, Weiden PJ, McEvoy JP, Harmer RM, Lieberman JA. 2008. Comparison of Atypicals in first Episode study group. Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomized, double-blind, flexible-dose, multi center study. J Clin Psychiatry 69:106–113.
   Google Scholar
• Robinson DG, Woerner MG, Delman HM, Kane JM. 2005. Pharmacological treatments for first-episode schizophrenia. Schizophr Bull 31:705–722.
   PubMed Web of Science ®Google Scholar
• Stroup TS, McEvoy JP, Swartz MS, Byerly MJ, Glick ID, Canive JM, et al. 2003. The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: Schizophrenia trial design and protocol development. Schizophr Bull 29:15–13.
   PubMed Web of Science ®Google Scholar
• Taylor M, Ng KY. 2013. Should long-acting (depot) antipsychotics be used in early schizophrenia? A systematic review. Aust N Z J Psychiatry 47(7):624–630.
   PubMedGoogle Scholar
• Verdoux H, Lengronne J, Liraud F, Gonzales B, Assens F, Abalan F, van Os J. 2000. Medication adherence in psychosis: predictors and impact on outcome. A 2-year follow-up of first-admitted subjects. Acta Psychiatr Scand 102:203–210.
   PubMed Web of Science ®Google Scholar
• Wiersma D, Nienhuis FJ, Slooff CJ, Giel R. 1998. Natural course of schizophrenic disorders: a 15-year follow-up of a Dutch incidence cohort. Schizophr Bull 24:75–85.
   PubMed Web of Science ®Google Scholar